Categories: HealthcareNews

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following two upcoming investor conferences:

  • Baird Global Healthcare Conference – New York, NY
    Tuesday, September 12, 2023, at 10:15 AM ET.
  • H.C. Wainwright & Co. Healthcare Conference – New York, NY
    Wednesday, September 13, 2023, at 3:30 PM ET.

A live webcast of the H.C Wainwright & Co. presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page. The Baird presentation is only available to clients of Baird.

Institutional investors interested in meeting with management during the conference may reach out to their Baird or H.C. Wainwright & Co. representatives.

About Solid Biosciences

Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne), AVB-401 a gene therapy program for the treatment of BAG3 mediated dilated cardiomyopathy, AVB-202-TT, a gene therapy program for the treatment of Friedreich’s Ataxia, and additional assets for the treatment of fatal cardiac diseases. Solid aims to be the center of excellence across a given disease spectrum bringing together those with expertise in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Leah Monteiro
VP, Investor Relations & Communications
617-821-4427
lmonteiro@solidbio.com

Staff

Recent Posts

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

2 hours ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

2 hours ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

2 hours ago

Shrub Oak International School Reinforces Unwavering Commitment to Student Safety and Security

MOHEGAN LAKE, N.Y., Dec. 5, 2025 /PRNewswire/ -- Shrub Oak International School today announced enhanced…

2 hours ago

‘I’D RATHER GET A ROOT CANAL’: US WORKERS DREAD THE OFFICE HOLIDAY PARTY

National poll reveals 27% of workers prefer dental work over office celebrations as workplace disconnection…

2 hours ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA…

2 hours ago